Tools for optimising treatment & management of advanced NETs

Prof. Emily Bergsland is a Professor of Medicine and the Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology at the University of California-San Francisco (UCSF). She has spent twenty years developing a clinical and research program focused on neuroendocrine tumours. Her clinical and research efforts are focused on advancing the care of patients with neuroendocrine neoplasms (NENs), understanding why NENs develop, and the development and testing of novel, biologically based therapies for NENs. Dr Bergsland is the Director of the University of California-San Francisco (UCSF) Centre for Neuroendocrine Tumours, Chair of the UCSF GI Oncology Site Committee and an active member of the Phase I Site Committee. Nationally, she is Chair of the Neuroendocrine Tumour Task Force of the National Cancer Institute (NCI) Gastrointestinal (GI) Steering Committee, a member of the NCCN Neuroendocrine Tumours Guidelines Panel, and is the current Vice-Chair (Chair-elect) of the North American Neuroendocrine Tumour Society (NANETS). She was also study chair for ALLIANCE A021202 (a randomized phase II trial of pazopanib v placebo in patients with progressive carcinoid tumours), a completed study which included a prospective plan for central review and archiving of serial radiologic images and blood sample collection for angiome profiling (analyses are pending).

Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.